Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Glioblastoma 3Lymphoma 2Sarcoma 1Recurrence 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Medulloblastoma 1Leukemia 1Gliosarcoma 1Glioma 1Carcinoma 1Astrocytoma 1

Interventions

Doxorubicin 27Cyclophosphamide 26Radiotherapy 16Gemcitabine 16Filgrastim 11pembrolizumab 10pazopanib 10Radiation 9Docetaxel 9Cisplatin 9fludarabine 7Trabectedin 7Ipilimumab 7Ifosfamide 7Granulocyte Colony-Stimulating Factor 7Etoposide 7Carboplatin 7Busulfan 7Bevacizumab 7olaratumab 6Temozolomide 6Peripheral Blood Stem Cell Transplantation 6Nivolumab 6Mesna 6Melphalan 6selinexor 5Leucovorin 5Irinotecan 5Celecoxib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma × Tetanus Toxoid × Clear all
NCT01644968 2022-05-17

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Providence Health & Services

Phase 1 Completed
30 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡